院内製剤の臨床使用に関する情報の実態調査

DOI Web Site Web Site PubMed 被引用文献1件

書誌事項

タイトル別名
  • Survey of Literature on the Development of an Evidence Database for Hospital-prepared Drugs in Japan
  • Symposium Review 院内製剤の臨床使用に関する情報の実態調査
  • Symposium Review インナイ セイザイ ノ リンショウ シヨウ ニ カンスル ジョウホウ ノ ジッタイ チョウサ

この論文をさがす

説明

　Hospital-prepared drugs (HP), known as In'Naiseizai in Japan, are custom-prepared formulations which offer medical professionals an alternative administration pathway by changing the formulation of existing drugs according to a patients' needs. Preparing the HP is one of several roles of pharmacists in providing personalized medicine at hospitals in Japan. In 2012, the Japanese Society of Hospital Pharmacists provided guidelines for the appropriate use of “Hospital-prepared drugs”. The following information was included in this guide: 1) documentation of the proper procedures, materials, prescription practices, etc., 2) required approval from the institutional review board of each HP on the risk-based classifications, and 3) to assess the stability, efficacy, and safety of each HP. However, several problems persist for pharmacists trying to prepare or use HP appropriately; the most common is insufficient manpower to both assess and prepare these drugs during routine hospital work. To resolve this problem, we are developing an evidence database for HP based on surveys of the current literature. This database has been developed for 109 drugs to date. Data-driven assessment of the stability of HP showed that 52 out of 109 drugs examined (47.7%). Notably, only 6 of the 109 HP (5.5%) in the database had all three characteristics of “stability”, “safety”, and “efficacy”. In conclusion, the application of this database will save manpower hours for hospital pharmacists in the preparation of HP. In the near future, we will make this database available to the wider medical community via the web or through literature.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 138 (6), 753-756, 2018-06-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ